Form 4: Fulgent Genetics' Chief Scientific Officer Gao Hanlin Reports Stock Transaction
SEC Form 4 Filing
Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On February 23, 2024, Fulgent Genetics' Chief Scientific Officer, Gao Hanlin, had 1,617 shares of common stock withheld to satisfy tax obligations.
- These obligations arose from the vesting of restricted stock units granted on February 23, 2023.
- The shares were withheld at a price of $24.06 per share.
- Following the transaction, Gao Hanlin beneficially owns 902,850 shares of Fulgent Genetics stock.
Sentiment
Score: 5
Explanation: This is a neutral report of a routine stock transaction related to executive compensation.
Industry Context
This is a routine disclosure related to executive compensation and tax obligations, common in publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 02/23/2023 | Date of original grant of restricted stock units to Gao Hanlin. |
| 02/23/2024 | Date of stock withholding for tax obligations. |
| 02/27/2023 | Date of original Form 4 filing reporting the grant of restricted stock units. |
| 02/27/2024 | Date of Form 4 filing reporting the stock transaction. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.